Alosetron, a serotonin 5-HT3 receptor antagonist, can cause ischemic colitis. The nurse should tell the client to report abdominal pain, bloody diarrhea, or rectal bleeding, and to stop taking the drug if these manifestations occur. Alosetron is more likely to cause anxiety. Clients who take alosetron, a serotonin 5-HT3 receptor antagonist, can develop severe constipation that can lead to impaction, bowel obstruction, perforation, and potentially fatal ischemic colitis. Because of these risks, nurses must inform clients of the benefits and risks of the drug therapy, and clients must sign a treatment agreement. Alosetron, a serotonin 5-HT3 receptor antagonist, treats the diarrhea and pain of severe irritable bowel syndrome. One formed stool per day indicates effective therapy. Alosetron is approved only to be prescribed to females who have IBS-D lasting 6 months or longer that has not been controlled by conventional treatment. Cimetidine: Cimetidine, a histamine2 receptor antagonist, can cause CNS effects, such as lethargy, depression, confusion, and seizures, especially in older adults. The nurse should instruct the client to report these manifestations. If they persist, the provider may prefer to prescribe ranitidine for the client. Can cause other manifestations, such as rash, alopecia, and Stevens-Johnson syndrome, fungal overgrowth in the stomach and mild diarrhea
Ranitidine: Antacids can decrease the absorption of ranitidine, a histamine2-receptor antagonist. The nurse should instruct the client to wait at least 1 hr between taking ranitidine and taking an antacid. long-term therapy with the drug can cause bone loss, so it requires monitoring of bone density. Ranitidine is a GI-system drug that is available in effervescent tablets to dissolve completely in water before swallowing. Ranitidine reduces the absorption of ketoconazole.
Sulfasalazine, a 5-aminosalicylate, is a GI-system drug that reduces the inflammation of inflammatory bowel disease. Photosensitivity is a possible adverse effect of sulfasalazine that makes the skin sensitive to light. The nurse should instruct the client to wear sunscreen and protective clothing when outdoors to prevent burning. Sulfasalazine interacts with iron and folic acid supplements and will reduce their absorption. The client should take iron and folic acid supplements separate from sulfasalazine. Skin integrity is correct. Sulfasalazine can cause a skin rash, so the nurse should check the client's skin for rashes. The drug can also cause nausea. If the client reports nausea, the nurse should suggest taking the drug with food or water.
Temperature is correct. Sulfasalazine can cause a fever, so the nurse should check the client's temperature and treat fever with an antipyretic. CBC is correct. Sulfasalazine can cause hematologic disorders, such as agranulocytosis and hemolytic and macrocytic anemia. The nurse should check the client's CBC periodically during therapy and tell the client to report sore throat or fatigue. Any sensitivity to salicylates, sulfonamides, or trimethoprim is a contraindication for the use of sulfasalazine, a 5-aminosalicylate. This is because intestinal bacteria metabolize the drug into 5-aminosalicylic acid, a salicylate. Aspirin is also a salicylate.
inhibits clotting by limiting the production of clotting factors VII, IX, X, and prothrombin. Warfarin inhibits vitamin K by preventing its activation. As a result, there is a decreased production of vitamin K dependent clotting factors VII, IX, X, and prothrombin. Vitamin K reverses the effects of warfarin by promoting the synthesis of coagulation factors VI, IX, X, and prothrombin. A chelating agent, such as deferoxamine, treats iron toxicity. It is ineffective for bleeding caused by an anticoagulant, such as warfarin. Warfarin is an anticoagulant drug that functions by inhibiting the action of vitamin K. Many foods, such as green, leafy vegetables, are rich in vitamin K. The client should maintain a consistent intake of vitamin K to avoid excesses or deficits and ensure the therapeutic effects of warfarin are consistent. a thrombolytic drug, can cause intracranial bleeding. The nurse should monitor the client for changes in level of consciousness, headache, one-sided weakness, and other indications of intracranial bleeding.
can cause bronchospasm, hypotension Alteplase is a thrombolytic drug. Thrombolytic drugs selectively convert plasminogen into the enzyme plasmin, which can actively breakdown the fibrin meshwork of a clot. Alteplase is a thrombolytic drug, meaning it can dissolve existing thrombi, whereas anticoagulant/antiplatelet drugs do not. An acute ischemic cerebrovascular event is often caused by the occlusion of a cerebral vessel by a thrombus. Administration of alteplase should be within 3 hr of the original onset of symptoms for the drug to be effective. Aminocaproic acid, a coagulator, inhibits fibrinolysis and stops excessive fibrinolytic bleeding, a severe adverse effect of alteplase.